This content is from: Podcasts

Podcast: Adams & Adams discusses trends in patent litigation across South Africa

Danie Dohmen and Russell Bagnall of Adams & Adams, and in-house counsel Natasha Wright, consider the recent trends in pharmaceutical patent litigation in South Africa and discuss how the enforcement environment evolved during the pandemic

In the third episode of the three-part podcast series by Adams & Adams on the IP enforcement of pharma in Africa, partners Danie Dohmen and Russell Bagnall, and in-house counsel Natasha Wright, talk to Managing IP about recent trends in pharmaceutical patent litigation in South Africa.

The experts discuss the nuances of the enforcement environment in South Africa amid the COVID-19 pandemic, specific pharma litigation enforcement proceedings, and the impact of the non-examination of patents, while providing examples to assist business leaders, innovators and consumers who work in the South African IP field.

About Adams & Adams

Adams & Adams is an internationally recognised and leading African law firm that specialises in providing intellectual property, corporate and commercial services.

The firm is firmly rooted in Africa – with a tenacious belief in the economic growth potential and spirit of the continent. The head office in Pretoria, the capital of South Africa, provides the perfect gateway through which our partners, supported by some 700 professionals and staff, render a broad range of legal services to clients in Africa and the rest of the world. 

Through its associate offices and long established networks, the firm serves a global client base throughout the African continent - in matters of intellectual property, commercial law, property and litigation.

Related content

Podcast: Adams & Adams discuss trends in anti-counterfeiting across Africa

Podcast: Adams & Adams discuss the challenges of registration in Africa

You can find all Managing IP podcasts here.

The material on this site is for law firms, companies and other IP specialists. It is for information only. Please read our Terms and Conditions and Privacy Notice before using the site. All material subject to strictly enforced copyright laws.

© 2021 Euromoney Institutional Investor PLC. For help please see our FAQs.

Instant access to all of our content. Membership Options | 30 Day Trial